# US 2023/0068832 A1 · Curcuminoid chemotherapeutic drug carrier composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068832 A1
- Document ID: US20230068832A1
- Status: Published application
- Kind: A1
- Application number: 17/938,150
- Filed: 2022-10-05
- Published: 2023-03-02
- Earliest claimed: 2018-08-06
- Assignees: Imam Abdulrahman Bin Faisal University
- Applicants: Imam Abdulrahman Bin Faisal University
- Inventors: B. Rabindran JERMY; Vijaya RAVINAYAGAM
- Web page: https://patentgrep.com/patent/US20230068832A1

## CPC

- A61K 31/12: Ketones
- A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 49/0428: {Surface-modified nanoparticles, e.g. immuno-nanoparticles}
- A61K 49/08: characterised by the carrier
- A61K 49/1878: {the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating}
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

## Claims

### Claim 1

A chemotherapeutic drug carrier composition, comprising:
a platform of nanoporous structured silica in the form of a mesocellular foam, superparamagnetic iron oxide nanoparticles (“SPIONS”) in an amount in a range of from 5 wt % to 20 wt % based on total weight of the composition, and
a curcuminoid loaded in a range of from 50 to 70 wt. %,
wherein the SPIONs have an average particle size in a range of from 13 to 58 nm,
wherein the platform loaded with the SPIONs has a BET surface area in a range of from 140 to 951 m2/g,
wherein the SPIONs comprise Fe2O3 or a mixture of NiFe2O4, CuFe2O4, MnFe2O4, or CoFe2O4, and
wherein the composition has a non-burst release profile with a cumulative curcuminoid release, in phosphate buffered saline at pH 5 and 37° C. over 3 hours, in a range of from 21.3 to 53.2 wt. %, relative to total curcuminoid content in the composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the platform of nanoporous structured silica is an MSU-foam.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The composition of claim 1, wherein the SPIONs comprise CoFe2O4.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the SPIONs comprise the Fe2O3 as γ-Fe2O3.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein one or more components of the composition is functionalized with at least one biocompatibilizer selected from the group consisting of chitosan, polyacrylic acid, and PLGA.

### Claim 9 (depends on 1)

The composition of claim 1, further comprising a polymer selected from the group consisting of chitosan, polyacrylic acid, and PLGA, wherein the SPIONs and/or the curcuminoid is covered with or incorporated into the polymer; and/or wherein one or more components of the composition is functionalized with at least one biocompatibilizer selected from the group consisting of chitosan, polyacrylic acid, and PLGA.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising an antibody part of the antibody that binds to a cancer, neoplasm, and/or a tumor cell.

### Claim 11 (depends on 1)

The composition of claim 1 that has a degree of magnetization in emu/g, as measured by vibrating sample magnetometry greater than an otherwise identical composition wherein the platform of nanoporous structured silica consists of mesocellular foam.

### Claim 12 (depends on 1)

The composition of claim 1 that has a percentage of cumulative curcuminoid release, in phosphate buffered saline at pH 5.6 and 37° C. over 72 hours, greater than an otherwise identical composition wherein the platform of nanoporous structured silica consists of mesocellular foam.

### Claim at position 13

13-20. (canceled)
